Answers are grounded in this paper and cite their sources.
The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
No takes yet. Share an insight, caveat, or question.
Papaemmanuil et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: